Newer Antibacterials in Therapy and Clinical Trials

Overview

Journal N Am J Med Sci

Specialty General Medicine

Date 2012 Nov 28

PMID 23181224

Citations 5

Authors

Simi S Paknikar

Sarala Narayana

Affiliations

Soon will be listed here.

Abstract

In order to deal with the rising problem of antibiotic resistance, newer antibacterials are being discovered and added to existing pool. Since the year 2000, however, only four new classes of antibacterials have been discovered. These include the oxazolidinones, glycolipopeptides, glycolipodepepsipeptide and pleuromutilins. Newer drugs were added to existing classes of antibiotics, such as streptogramins, quinolones, beta-lactam antibiotics, and macrolide-, tetracycline- and trimethoprim-related drugs. Most of the antibacterials are directed against resistant S. aureus infections, with very few against resistant gram-negative infections. The following article reviews the antibacterials approved by the FDA after the year 2000 as well as some of those in clinical trials. Data was obtained through a literature search via Pubmed and google as well as a detailed search of our library database.

Citing Articles

Pathogen Box screening for hit identification against Mycobacterium abscessus.

Jeong J, Kim G, Moon C, Kim H, Kim T, Jang J PLoS One. 2018; 13(4):e0195595.

PMID: 29698397 PMC: 5919404. DOI: 10.1371/journal.pone.0195595.

Envelope Structures of Gram-Positive Bacteria.

Rajagopal M, Walker S Curr Top Microbiol Immunol. 2016; 404:1-44.

PMID: 26919863 PMC: 5002265. DOI: 10.1007/82_2015_5021.

Antibiotic resistance in sepsis patients: evaluation and recommendation of antibiotic use.

Pradipta I, Sodik D, Lestari K, Parwati I, Halimah E, Diantini A N Am J Med Sci. 2013; 5(6):344-52.

PMID: 23923107 PMC: 3731864. DOI: 10.4103/1947-2714.114165.

Advances in MRSA drug discovery: where are we and where do we need to be?.

Kurosu M, Siricilla S, Mitachi K Expert Opin Drug Discov. 2013; 8(9):1095-116.

PMID: 23829425 PMC: 3750092. DOI: 10.1517/17460441.2013.807246.

Bacteriology of symptomatic adenoids in children.

Rajeshwary A, Rai S, Somayaji G, Pai V N Am J Med Sci. 2013; 5(2):113-8.

PMID: 23641372 PMC: 3624711. DOI: 10.4103/1947-2714.107529.

References

Devasahayam G, Scheld W, Hoffman P . Newer antibacterial drugs for a new century. Expert Opin Investig Drugs. 2010; 19(2):215-34. PMC: 2831224. DOI: 10.1517/13543780903505092. View

Betriu C, Morales G, Rodriguez-Avial I, Culebras E, Gomez M, Lopez-Fabal F . Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob Agents Chemother. 2010; 54(5):2212-5. PMC: 2863658. DOI: 10.1128/AAC.01653-09. View

Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta J . Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2010; 55(2):583-92. PMC: 3028792. DOI: 10.1128/AAC.00076-10. View

Manfredi R, Sabbatani S . Novel pharmaceutical molecules against emerging resistant gram-positive cocci. Braz J Infect Dis. 2010; 14(1):96-108. DOI: 10.1590/s1413-86702010000100020. View

Abbanat D, Morrow B, Bush K . New agents in development for the treatment of bacterial infections. Curr Opin Pharmacol. 2008; 8(5):582-92. DOI: 10.1016/j.coph.2008.08.001. View

Politano A, Sawyer R . NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA. Curr Opin Investig Drugs. 2010; 11(2):225-36. PMC: 3033781. View

Steenbergen J, Alder J, Thorne G, Tally F . Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005; 55(3):283-8. DOI: 10.1093/jac/dkh546. View

Comstock T, Karpecki P, Morris T, Zhang J . Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis. Clin Ophthalmol. 2010; 4:215-25. PMC: 2861926. DOI: 10.2147/opth.s9604. View

Morrissey I, Tillotson G . Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother. 2004; 53(2):144-8. DOI: 10.1093/jac/dkh092. View

10.

Shah P, Isaacs R . Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother. 2003; 52(4):538-42. DOI: 10.1093/jac/dkg404. View

11.

El Solh A . Ceftobiprole: a new broad spectrum cephalosporin. Expert Opin Pharmacother. 2009; 10(10):1675-86. DOI: 10.1517/14656560903048967. View

12.

Lemaire S, Kosowska-Shick K, Appelbaum P, Verween G, Tulkens P, Van Bambeke F . Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother. 2010; 54(6):2549-59. PMC: 2876393. DOI: 10.1128/AAC.01724-09. View

13.

Barberan J, Mensa J . [Cefditoren and community-acquired lower respiratory tract infections (corrected)]. Rev Esp Quimioter. 2009; 22(3):144-50. View

14.

Paterson D, DePestel D . Doripenem. Clin Infect Dis. 2009; 49(2):291-8. DOI: 10.1086/600036. View

15.

Lonks J, Goldmann D . Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis. 2005; 40(11):1657-64. DOI: 10.1086/430067. View

16.

Guskey M, Tsuji B . A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2009; 30(1):80-94. DOI: 10.1592/phco.30.1.80. View

17.

van Rensburg D, Perng R, Mitha I, Bester A, Kasumba J, Wu R . Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother. 2010; 54(10):4098-106. PMC: 2944601. DOI: 10.1128/AAC.00295-10. View

18.

Rafie S, MacDougall C, James C . Cethromycin: a promising new ketolide antibiotic for respiratory infections. Pharmacotherapy. 2010; 30(3):290-303. DOI: 10.1592/phco.30.3.290. View

19.

Blasi F, Aliberti S, Tarsia P, Santus P, Centanni S, Allegra L . Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis. 2007; 2(1):27-31. PMC: 2692114. DOI: 10.2147/copd.2007.2.1.27. View

20.

Dunbar L, Tang D, Manausa R . A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Ther Clin Risk Manag. 2008; 4(1):235-44. PMC: 2503659. DOI: 10.2147/tcrm.s1843. View